2026: Patents Granted to Animal Health Companies in First Half of 2026

This is part of our series on the Market Intelligence covering All Patents Granted in the field of Animal Health, for the period January – June 2026. A detailed list of all, major patents granted in the first half of 2026 is listed below, followed by a summary of all the patents granted in 2026, so far. Savour the details..

PATENTS: January – June 2026

The first half of 2026 (January to June) was a highly strategic period for global animal health intellectual property, dominated by the commercialization of veterinary monoclonal antibodies (mAbs) for chronic pet conditions, advanced isoxazoline parasiticide formulations, and AI-driven AgTech biodevices.

The company-wise breakdown maps verified patents granted, key patent applications advanced, and major IP-driven acquisitions executed between January 1 and June 30, 2026:

1. Zoetis Inc.

The global animal health industry leader heavily expanded its portfolio in Precision Animal Health and high-value companion animals’ diagnostics during the first half of 2026.

• Key Acquisition-Linked IP (March 2026): Zoetis finalised a definitive $160 million agreement to acquire the animal genomics business from Neogen Corporation. This move absorbs Neogen’s comprehensive genotyping platform patents (fixed array and sequencing technologies) into Zoetis’ predictive livestock portfolio.

• Diagnostic Award Validation (March 2026): Zoetis’ Vetscan OptiCell™—a proprietary, automated AI-driven companion animal haematology platform—won top honours at the S&P Global Animal Health Awards, validating a series of machine-learning cellular recognition software patents filed over the prior 24 months.

2. Elanco US Inc.

Elanco captured several foundational utility patents during the H1 2026 window, focusing on multi-agent formulations and canine immunology.

• US Patent 12,583,917 B2 (Granted March 24, 2026): “IL17A antibodies and antagonists for veterinary use.” This patent explicitly protects veterinary anti-IL17A antibodies and IgG Fc variant polypeptides engineered to reduce C1q and CD16 binding. This represents a long-term therapeutic play against chronic dermatitis and auto-immune conditions in canines and felines.

• US Patent 12,544,336 B2 (Granted February 10, 2026): “Palatable formulations.” Protects a multi-agent oral dosage treat that packs a high-efficiency isoxazoline parasiticidal agent, an avermectin, and praziquantel into a single chewable. It targets broad-spectrum internal and external parasites simultaneously.

• US Patent Application 20260092107A1 (Published April 2, 2026): “Anti-IL31 antibodies binding to canine IL31.” Advanced chemical configurations targeting atopic dermatitis to directly rival established monoclonal antibody therapies.

3. IDEXX Laboratories, Inc.

IDEXX focused its H1 2026 patent strategy on advanced diagnostic logic and molecular antigen detection frameworks.

• Reference Lab Integration (June 2026): Automated updates rolled out across North American reference labs for the Fecal Dx® antigen testing platform. This structural deployment utilizes automated multiplexing software patents to spot taeniid tapeworm (Taenia and Echinococcus) surface antigens weeks before eggs are morphologically visible in stool samples.

4. Merck Animal Health (MSD Animal Health)

Merck executed a major strategic pivot in the second quarter of 2026, shifting its IP asset mix from pure chemistry to advanced AgTech biodevices.

• Blockbuster IP Acquisition (June 11, 2026): Merck entered into a definitive agreement to fully acquire TARGAN, an AgTech system innovator. This acquisition shifts a highly lucrative collection of biodevice utility patents directly into Merck’s commercial hatchery pipeline:

  • WingScan™ Technology: Patented high-speed vision algorithms and proprietary imaging hardware capable of checking and sorting up to 160,000 day-old chicks per hour by gender using real-time feather feather feather scanning.

  • High-Speed Ocular Spray Systems: Patented fluid-mechanic micro-nozzles designed to simultaneously administer respiratory and coccidiosis vaccines to newly hatched poultry cohorts.

5. Boehringer Ingelheim Animal Health

Boehringer focused its H1 2026 innovation framework on collaborative platforms and mRNA vaccine tech integration.

• Strategic Platform Consolidation (Mid-2026): Boehringer began the active integration of novel therapeutic vaccine technology platforms acquired from Saiba Animal Health, securing early-stage patent protections for virus-like particles (VLPs) engineered to treat chronic canine pain, atopy, and obesity.

• AI Cardiology Expansion: Collaborating with Eko Health, the firm advanced software patent structures combining digital stethoscopes with AI algorithms to detect canine murmur conditions early.

6. BiomEdit LLC

• US Patent 12,599,637 & 12,427,174 (Granted April 2026): “Genetically Modified Lactobacillus and Uses Thereof.” This milestone biological patent duo protects BiomEdit’s engineered probiotic vectored antibody platform. The lead product protected under this formulation, BE-101, delivers targeted local biologicals inside the avian intestine to neutralize Clostridium perfringens without conventional antibiotics.

7. ICAR-NIVEDI / ICMR (India)

• Indian Patent No. 589492 (Granted May 15, 2026): Formally granted to the Indian Council of Agricultural Research (ICAR) and the Indian Council of Medical Research (ICMR). The patent covers a highly sensitive Recombinant Leptospiral Surface Antigen-Based Immuno-Diagnostic Test designed for swift, point-of-care Leptospirosis identification across livestock populations and zoonotic human interfaces.

Concise Company-wise Summary